 |
|
Expanding Newborn Screening
How Good Is the Evidence?
Neil A. Holtzman, MD, MPH
JAMA. 2003;290:2606-2608.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
State health departments have been reluctant to adopt tandem mass spectrometry for newborn screening because of its expense (start-up cost of about $400 0001) and doubts about its validity and utility. However, pressure to adopt the screening technology has come from medicolegal proceedings brought by parents of infants with genetic disorders who were not screened and from the direct lobbying of hospitals and health departments by advocacy groups (http://www.savebabies.org). In addition, a private screening laboratory, Pediatrix Inc (formerly NeoGen Screening Inc), markets tandem mass spectrometry to hospitals and states. Despite the continuing lack of evidence regarding its safety and effectiveness, tandem mass spectrometry is now mandated in 24 states (http://genes-r-us.uthscsa.edu).
In this issue of THE JOURNAL, Waisbren et al2 provide data that enable clinicians, policy makers, and others to begin to assess the validity and utility of tandem mass spectrometry. The . . . [Full Text of this Article]
Author Affiliations: Department of Pediatrics, Johns Hopkins University School of Medicine; Health Policy and Management, Department of Epidemiology, Bloomberg School of Public Health, Genetics and Public Policy Studies, Johns Hopkins University, Baltimore, Md.
RELATED LETTERS
Expanded Screening of Newborns for Genetic Disorders
Susan E. Waisbren and Harvey L. Levy
JAMA. 2004;291(7):820-821.
EXTRACT
| FULL TEXT
Expanded Screening of Newborns for Genetic Disorders—Reply
Neil A. Holtzman
JAMA. 2004;291(7):821.
EXTRACT
| FULL TEXT
RELATED ARTICLE
Effect of Expanded Newborn Screening for Biochemical Genetic Disorders on Child Outcomes and Parental Stress
Susan E. Waisbren, Simone Albers, Steve Amato, Mary Ampola, Thomas G. Brewster, Laurie Demmer, Roger B. Eaton, Robert Greenstein, Mark Korson, Cecilia Larson, Deborah Marsden, Michael Msall, Edwin W. Naylor, Siegfried Pueschel, Margretta Seashore, Vivian E. Shih, and Harvey L. Levy
JAMA. 2003;290(19):2564-2572.
ABSTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Newborn Screening: Complexities in Universal Genetic Testing
Green et al.
Am. J. Public Health 2006;96:1955-1959.
ABSTRACT
| FULL TEXT
Privatization of Public Services: Organizational Reform Efforts in Public Education and Public Health
Gollust and Jacobson
Am. J. Public Health 2006;96:1733-1739.
ABSTRACT
| FULL TEXT
Clinical, biochemical, and genetic heterogeneity in short-chain acyl-coenzyme A dehydrogenase deficiency.
van Maldegem et al.
JAMA 2006;296:943-952.
ABSTRACT
| FULL TEXT
Newborn Screening Technology: Proceed With Caution
Botkin et al.
Pediatrics 2006;117:1793-1799.
FULL TEXT
Tandem Mass Spectrometry Program Implementation Challenges for State Newborn Screening Programs: National Survey of Barriers and Issues
Feuchtbaum et al.
Pediatrics 2006;117:S253-S260.
ABSTRACT
| FULL TEXT
Newborn Screening -- Setting Evidence-Based Policy for Protection
Natowicz
NEJM 2005;353:867-870.
FULL TEXT
Making Policy When The Evidence Is In Dispute
Atkins et al.
Health Aff (Millwood) 2005;24:102-113.
ABSTRACT
| FULL TEXT
Management of Hyperbilirubinemia: Quality of Evidence and Cost
Holtzman
Pediatrics 2004;114:1086-1088.
FULL TEXT
Expanded Screening of Newborns for Genetic Disorders
Waisbren and Levy
JAMA 2004;291:820-821.
FULL TEXT
Expanded Newborn Screening Tests: Do the Benefits Exceed the Risks?
Springer
AAP Grand Rounds 2004;11:14-15.
FULL TEXT
|
